The international lamotrigine pregnancy registry update for the epilepsy foundation

Epilepsia

Volumn 45, Issue 11, 2004, Pages 1468-

  Cunnington, Marianne C ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LAMOTRIGINE; VALPROIC ACID;

CONGENITAL MALFORMATION; EPILEPSY; HUMAN; INTERNATIONAL COOPERATION; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REGISTER; RISK ASSESSMENT; SHORT SURVEY;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; EPILEPSY; FEMALE; FOUNDATIONS; HUMANS; INFANT, NEWBORN; INTERNATIONAL COOPERATION; PREGNANCY; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; TRIAZINES; WORLD HEALTH;

EID: 19644401206     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0013-9580.2004.451105.x     Document Type: Short Survey

References (4)

1. Honein MA, Paulozzi LJ, Cragan JD, et al. Evaluation of selected characteristics of pregnancy drug registries. Teratology 1999;60:356-64.
2. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001;344:1132-38.
3. Samrén EB, van Duijn CM, Christiaens GC. Antiepileptic drug regimens and major congential abnormalities in the offspring. Ann Neurol 1999;46:739-46.
4. Marrow JI, Craig JJ, Russell AJC, et al. Which antiepileptic drugs are safest in pregnancy. Epilepsia 2003;44(suppl 8):P096.